You have 9 free searches left this month | for more free features.

somatostatin receptor positive tumour

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Neuroendocrine Carcinoma Trial in London (Lu-DOTA-TATE)

Active, not recruiting
  • Neuroendocrine Carcinoma
  • Lu-DOTA-TATE
  • London, Ontario, Canada
    London Health Sciences Centre
Apr 5, 2022

Breast Cancer Stage IV Trial in Irvine (Gallium-68)

Recruiting
  • Breast Cancer Stage IV
  • Irvine, California
    Hoag Memorial Hospital Presbyterian
May 26, 2023

Neuroendocrine Tumors Trial in Beijing (Lutetium[177Lu] Oxodotreotide Injection)

Not yet recruiting
  • Neuroendocrine Tumors
  • Lutetium[177Lu] Oxodotreotide Injection
  • Beijing, Beijing, China
    Beijing Cancer Hospital
May 30, 2023

Neuroendocrine Tumors, Carcinoid Tumor, Pulmonary Carcinoid Tumor Trial in Vancouver (177Lu-DOTATOC)

Not yet recruiting
  • Neuroendocrine Tumors
  • +6 more
  • Vancouver, British Columbia, Canada
    BC Cancer
Aug 19, 2022

Lutathera® in Somatostatin Receptor Positive

Recruiting
  • Somatostatin Receptor-positive GEP-NET
  • Lutathera
  • Seongnam Si, Gyeonggi Do, Korea, Republic of
  • +4 more
Jun 29, 2022

Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour Trial in Worldwide (Octreotide LAR, 177Lu-DOTA0-Tyr3-Octreotate)

Completed
  • Carcinoid Tumor of the Small Bowel
  • Neuroendocrine Tumour
  • Los Angeles, California
  • +38 more
Mar 10, 2022

68-Ga DOTATATE PET/MRI in Diagnosis and Management of

Recruiting
  • CNS Tumors
  • +6 more
  • Ga68-DOTATATE-PET/MRI
  • New York, New York
    Weill Cornell Medicine
Sep 20, 2022

Neuroendocrine Tumors Trial in Edmonton (68Ga-HA-DOTATATE)

Recruiting
  • Neuroendocrine Tumors
  • Edmonton, Alberta, Canada
    University of Alberta
Apr 11, 2022

Neuroendocrine Tumors, Meningioma, Neuroblastoma Trial in Iowa City (radiation, diagnostic test, drug)

Active, not recruiting
  • Neuroendocrine Tumors
  • +3 more
  • 90Y-DOTA tyr3-Octreotide
  • +2 more
  • Iowa City, Iowa
    University of Iowa Hospitals and Clinics
Oct 6, 2022

Neuroendocrine Neoplasia's (NENs), Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) Trial in Basel (161Tb-DOTA-LM3,

Not yet recruiting
  • Neuroendocrine Neoplasia's (NENs)
  • Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
  • Basel, Switzerland
    Division of Nuclear Medicine, University Hospital Basel
Apr 27, 2022

Neuroendocrine Tumors Trial in Portland (Cabozantinib, Lu-177)

Not yet recruiting
  • Neuroendocrine Tumors
  • Portland, Oregon
    Providence Portland Cancer Institute - Franz Clinic
Feb 10, 2022

LUTATHERA Injection General Use Result Survey

Recruiting
  • Somatostatin Receptor-positive Neuroendocrine Tumor
  • LUTATHERA
  • Kashiwa, Chiba, Japan
  • +6 more
Apr 25, 2023

Small Cell Lung Cancer and Breast Cancer Trial in Worldwide (Satoreotide tetraxetan, Satoreotide trizoxetan)

Terminated
  • Small Cell Lung Cancer and Breast Cancer
  • Satoreotide tetraxetan
  • Satoreotide trizoxetan
  • Houston, Texas
  • +7 more
Aug 22, 2022

Advanced Lung Carcinoid Tumor, Functioning Lung Carcinoid Tumor, Locally Advanced Lung Neuroendocrine Tumor Trial in Boston,

Recruiting
  • Advanced Lung Carcinoid Tumor
  • +11 more
  • Boston, Massachusetts
  • +1 more
Jul 19, 2022

Effectiveness and Outcomes Associated With Lutathera Treatment

Active, not recruiting
  • Gastroenteropancreatic Neuroendocrine Tumor
  • Alessandria, Italy
  • +17 more
May 4, 2022

Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor Trial in Madison (Single Photon Emission Computed

Not yet recruiting
  • Neuroendocrine Tumors
  • Somatostatin Receptor-positive Neuroendocrine Tumor
  • Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)
  • +3 more
  • Madison, Wisconsin
    University of Wisconsin - Madison
Nov 2, 2023

Advanced Gastroenteropancreatic Neuroendocrine Tumor Trial (Lutetium (177Lu) Oxodotreotide Injection;long-acting Octreotide,

Not yet recruiting
  • Advanced Gastroenteropancreatic Neuroendocrine Tumor
  • Lutetium (177Lu) Oxodotreotide Injection;long-acting Octreotide
  • long-acting Octreotide.
  • (no location specified)
May 22, 2023

Neuroendocrine Tumors Trial in China (Lutetium[177Lu] Oxodotreotide Injection, Octreotide LAR)

Not yet recruiting
  • Neuroendocrine Tumors
  • Lutetium[177Lu] Oxodotreotide Injection
  • Octreotide LAR
  • Beijing, Beijing, China
  • +20 more
Jul 25, 2022

Metastatic Neuroendocrine Tumor Trial (Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate)

Not yet recruiting
  • Metastatic Neuroendocrine Tumor
  • Biospecimen Collection
  • +4 more
  • (no location specified)
Feb 10, 2023

NSCLC, EGF-R Positive NSCLC Trial in Shanghai (Furmonertinib)

Recruiting
  • NSCLC
  • EGF-R Positive Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai General Hospital
Jan 12, 2022

Neuroendocrine Tumors Trial in Worldwide (177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine

Recruiting
  • Neuroendocrine Tumors
  • 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT
  • +4 more
  • Palo Alto, California
  • +30 more
Dec 14, 2022

Neuroendocrine Tumors Trial in Edmonton ([68]Ga-HA-DOTATATE)

Recruiting
  • Neuroendocrine Tumors
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Jun 18, 2021

Carcinoma, Neuroendocrine Trial in Edmonton ([177]Lu-DOTA-TATE)

Recruiting
  • Carcinoma, Neuroendocrine
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Apr 12, 2021

Adult Medulloblastoma, Childhood Medulloblastoma, Neuroblastoma Trial in Iowa City (drug, procedure, radiation)

Completed
  • Adult Medulloblastoma
  • +4 more
  • gallium Ga 68-edotreotide
  • +4 more
  • Iowa City, Iowa
    University of Iowa Hospitals and Clinics
Aug 26, 2021